PCN Insights, News, Videos, and More
Videos
10/05/2023
With Veronica Ridpath, DO
With Veronica Ridpath, DO
Dr Veronica Ridpath on bipolar disorder treatment
Dr Veronica Ridpath on bipolar disorder treatment
Dr Veronica Ridpath on bipolar...
10/05/2023
Psych Congress Network
News
10/03/2023
Digital therapeutics have the potential to reduce experiential negative symptoms (ENS) in patients with schizophrenia, according to poster findings presented at Psych Congress 2023 in Nashville, Tennessee.
Digital therapeutics have the potential to reduce experiential negative symptoms (ENS) in patients with schizophrenia, according to poster findings presented at Psych Congress 2023 in Nashville, Tennessee.
Digital therapeutics have the...
10/03/2023
Psych Congress Network
News
10/02/2023
Tom Valentino, Digital Managing Editor
Treating depression could help to reduce sexual dysfunction in patients with schizophrenia, according to a recent study.
Treating depression could help to reduce sexual dysfunction in patients with schizophrenia, according to a recent study.
Treating depression could help...
10/02/2023
Psych Congress Network
News
10/02/2023
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training...
10/02/2023
Psych Congress Network
Videos
10/01/2023
Featuring Craig Chepke, MD, DFAPA
Featuring Craig Chepke, MD, DFAPA
...
Craig Chepke, MD, DFAPA, discusses the latest advancements in the understanding of tardive dyskinesia and how clinicians can adapt their assessment and management strategies with this updated knowledge.
Craig Chepke, MD, DFAPA, discusses the latest advancements in the understanding of tardive dyskinesia and how clinicians can adapt their assessment and management strategies with this updated knowledge.
Craig Chepke, MD, DFAPA,...
10/01/2023
Psych Congress Network
News
10/01/2023
A recent pilot randomized clinical trial found that esketamine may be an effective, safe treatment for fluctuating antidepressant response in patients with MDD.
A recent pilot randomized clinical trial found that esketamine may be an effective, safe treatment for fluctuating antidepressant response in patients with MDD.
A recent pilot randomized...
10/01/2023
Psych Congress Network
Schizophrenia Insights
09/27/2023
Featuring Veronica Ridpath, DO
Featuring Veronica Ridpath, DO
...
Veronica Ridpath, DO, addresses clinician bias towards the use of long-acting injectables for schizophrenia treatment.
Veronica Ridpath, DO, addresses clinician bias towards the use of long-acting injectables for schizophrenia treatment.
Veronica Ridpath, DO, addresses...
09/27/2023
Psych Congress Network
News
09/27/2023
Gray matter changes that occur across different stages of psychosis may begin in the hippocampus, suggest study results published in JAMA Psychiatry.
Gray matter changes that occur across different stages of psychosis may begin in the hippocampus, suggest study results published in JAMA Psychiatry.
Gray matter changes that occur...
09/27/2023
Neurology
News
09/26/2023
Tom Valentino, Digital Managing Editor
Psychiatrists, psychotherapists, and addiction treatment professionals will convene at HMP Global’s online event to share research updates and provide a multi-perspective view on the potential application and approaches of psychedelic...
Psychiatrists, psychotherapists, and addiction treatment professionals will convene at HMP Global’s online event to share research updates and provide a multi-perspective view on the potential application and approaches of psychedelic...
Psychiatrists, psychotherapists,...
09/26/2023
Psych Congress Network
News
09/25/2023
Tom Valentino, Digital Managing Editor
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3...
09/25/2023
Psych Congress Network
